Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cressey

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014
Raltegravir pharmacokinetics during pregnancyD Heather Watts, Alice Stek, Brookie M Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2016
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant WomenAnna H Tran, Brookie M Best, Alice Stek, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 2, 2021
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE StudyAdrie Bekker, Helena Rabie, Nicolas Salvadori, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 18, 2017
Brief Report: AIDS-Defining Events and Deaths in HIV-Infected Children and Adolescents on Antiretrovirals: A 14-Year Study in ThailandPatrinee Traisathit, Tristan Delory, Nicole Ngo-Giang-Huong, et al.
Plos One|May 21, 2015
Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIVPatumrat Sripan, Sophie Le Coeur, Billy Amzal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 18, 2019
Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study)Paul K Drain, Rachel W Kubiak, Oraphan Siriprakaisil, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 25, 2020
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before DeliveryMarc Lallemant, Billy Amzal, Patumrat Sripan, et al.
Clinical Pharmacokinetics|March 10, 2018
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant WomenStein Schalkwijk, Rob Ter Heine, Angela C Colbers, et al.
AIDS (London, England)|October 22, 2019
Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settingsMonica Gandhi, Guohong Wang, Roger King, et al.
Clinical Pharmacology and Therapeutics|September 15, 2020
Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus StatementAhizechukwu C Eke, Adeniyi Olagunju, Jeremiah Momper, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014
Raltegravir pharmacokinetics during pregnancyD Heather Watts, Alice Stek, Brookie M Best, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2016
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant WomenAnna H Tran, Brookie M Best, Alice Stek, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 2, 2021
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE StudyAdrie Bekker, Helena Rabie, Nicolas Salvadori, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 18, 2017
Brief Report: AIDS-Defining Events and Deaths in HIV-Infected Children and Adolescents on Antiretrovirals: A 14-Year Study in ThailandPatrinee Traisathit, Tristan Delory, Nicole Ngo-Giang-Huong, et al.
Plos One|May 21, 2015
Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIVPatumrat Sripan, Sophie Le Coeur, Billy Amzal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 18, 2019
Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study)Paul K Drain, Rachel W Kubiak, Oraphan Siriprakaisil, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 25, 2020
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before DeliveryMarc Lallemant, Billy Amzal, Patumrat Sripan, et al.
Clinical Pharmacokinetics|March 10, 2018
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant WomenStein Schalkwijk, Rob Ter Heine, Angela C Colbers, et al.
AIDS (London, England)|October 22, 2019
Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settingsMonica Gandhi, Guohong Wang, Roger King, et al.
Clinical Pharmacology and Therapeutics|September 15, 2020
Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus StatementAhizechukwu C Eke, Adeniyi Olagunju, Jeremiah Momper, et al.
Pageof 16